C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA)
C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA)
